Recruiting
Phase 2

A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease

Sponsor:

Sanofi

Code:

NCT06557772

Conditions

Coeliac Disease

Celiac Disease

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Amlitelimab

Placebo

SIGE

Gluten-free product (GFP)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information